At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OMER Omeros
Pre-Mkt 07-23 06:26:30 EDT
9.84
+0.31
+3.25%
盘前10.06
+0.22+2.24%
04:50 EDT
High9.91Low9.43Vol1.23M
Open9.43D1 Closing9.53Amplitude5.09%
Mkt Cap712.17MTradable Cap671.54MTotal Shares72.38M
T/O12.02MT/O Rate1.80%Tradable Shares68.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Omeros Reduces Convertible Debt Through Note Repurchases
TIPRANKS  ·  07-21 05:28
Omeros Reduces Convertible Debt Through Note Repurchases
Omeros Repurchases USD 14.5 Million of 9.5% Convertible Notes Due 2029 for USD 29 Million
Reuters  ·  07-21 05:05
Omeros Repurchases USD 14.5 Million of 9.5% Convertible Notes Due 2029 for USD 29 Million
Ema: Omeros Ireland Requested Re-examination of Ema's Opinion on Yartemlea Issued on 25 June - Website
THOMSON REUTERS  ·  07-15
Ema: Omeros Ireland Requested Re-examination of Ema's Opinion on Yartemlea Issued on 25 June - Website
Omeros Expects to Complete Repurchase of $16 Million of 9.5% Convertible Notes Due 2029 for About $31.3 Million
Reuters  ·  07-06
Omeros Expects to Complete Repurchase of $16 Million of 9.5% Convertible Notes Due 2029 for About $31.3 Million
Omeros is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  06-26
Omeros is Maintained at Buy by HC Wainwright & Co.
Omeros price target lowered to $33 from $40 at H.C. Wainwright
TIPRANKS  ·  06-26
Omeros price target lowered to $33 from $40 at H.C. Wainwright
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide
Benzinga  ·  06-26
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide
Omeros Falls on Negative EU Opinion for Transplant Drug
Reuters  ·  06-26
Omeros Falls on Negative EU Opinion for Transplant Drug
Omeros Faces Negative EMA Panel Opinion on Narsoplimab Marketing Application for Ta-tma
Reuters  ·  06-26
Omeros Faces Negative EMA Panel Opinion on Narsoplimab Marketing Application for Ta-tma
Omeros Corp - Chmp Adopts Negative Opinion on Narsoplimab Maa for Ta-tma
THOMSON REUTERS  ·  06-26
Omeros Corp - Chmp Adopts Negative Opinion on Narsoplimab Maa for Ta-tma
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in Ta-tma
THOMSON REUTERS  ·  06-26
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in Ta-tma
Omeros Corp - to Request Re-examination of Chmp Opinion and Review by Ad Hoc Expert Group
THOMSON REUTERS  ·  06-26
Omeros Corp - to Request Re-examination of Chmp Opinion and Review by Ad Hoc Expert Group
Top Premarket Decliners
MT Newswires Live  ·  06-26
Top Premarket Decliners
Omeros Shareholders Approve Executive Pay in Advisory Vote at Annual Meeting
Reuters  ·  06-25
Omeros Shareholders Approve Executive Pay in Advisory Vote at Annual Meeting
Omeros agrees to repurchase up to $16 million of 9.5% convertible notes due 2029 for up to $34 million
Reuters  ·  06-18
Omeros agrees to repurchase up to $16 million of 9.5% convertible notes due 2029 for up to $34 million
Omeros announces annual shareholder meeting webcast details
Reuters  ·  06-15
Omeros announces annual shareholder meeting webcast details
Omeros trading resumes
TIPRANKS  ·  06-12
Omeros trading resumes
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
Reuters  ·  06-12
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
Omeros Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-10
Omeros Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
H.C. Wainwright Keeps Their Buy Rating on Omeros (OMER)
TIPRANKS  ·  06-10
H.C. Wainwright Keeps Their Buy Rating on Omeros (OMER)

Introduction

Company Name.
Omeros
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Issue price:
--